Woonghee
Lee
a,
Kondapa Naidu
Bobba
a,
Jung Young
Kim
b,
Hyun
Park
b,
Abhinav
Bhise
a,
Wanook
Kim
a,
Kiwoong
Lee
a,
Subramani
Rajkumar
a,
Bora
Nam
a,
Kyo Chul
Lee
b,
Sang Hyuk
Lee
c,
Sanghwan
Ko
de,
Hye Jin
Lee
c,
Sang Taek
Jung
de and
Jeongsoo
Yoo
*a
aDepartment of Molecular Medicine, Brain Korea 21 four KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea. E-mail: yooj@knu.ac.kr
bDivision of Applied RI, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea
cDepartment of Chemistry and Green-Nano Materials Research Center, Kyungpook National University, 80 Daehakro, Buk-gu, Daegu 41566, Republic of Korea
dBK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Republic of Korea
eInstitute of Human Genetics, Korea University College of Medicine, Seoul 02841, Republic of Korea
First published on 27th July 2021
Correction for ‘A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high-contrast immuno-PET images’ by Woonghee Lee et al., J. Mater. Chem. B, 2021, 9, 2993–2997, DOI: 10.1039/D0TB02911D.
‘This work was supported by the R&D program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (No. 2019R1A2C2084313, 2020M2D8A3094031 and 2019H1D3A1A01102643). This research was partially supported by Kyungpook National University Development Project Research Fund, 2018. The Korea Basic Science Institute is acknowledged for MALDI-MS measurements.’
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2021 |